Investigating how a specific lipid affects heart inflammation and failure in obese patients
Lysophosphatidic acid mediates cardiac inflammation and heart failure with preserved ejection fraction
This study is looking at how a substance called lysophosphatidic acid (LPA) affects heart inflammation and heart failure in people who are obese, with the goal of finding new ways to help improve their heart health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Veterans Health Administration NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10975915 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of lysophosphatidic acid (LPA) in cardiac inflammation and heart failure with preserved ejection fraction (HFpEF), particularly in obese individuals. The study aims to explore the mechanisms by which obesity-induced inflammation contributes to HFpEF, a condition that significantly impacts the health of many patients. By examining the levels of LPA and its effects on cardiac signaling and remodeling, the research seeks to identify potential therapeutic targets for improving patient outcomes. The approach includes analyzing plasma levels of LPA and related biomarkers in both human patients and animal models to establish a clearer understanding of the underlying processes.
Who could benefit from this research
Good fit: Ideal candidates for this research are obese individuals who are at risk for or diagnosed with heart failure with preserved ejection fraction (HFpEF).
Not a fit: Patients who are not obese or do not have heart failure with preserved ejection fraction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target cardiac inflammation in obese patients, potentially improving their heart health and quality of life.
How similar studies have performed: While there have been studies on inflammation and heart failure, the specific focus on lysophosphatidic acid in the context of HFpEF in obese patients is relatively novel and has not been extensively tested.
Where this research is happening
Ann Arbor, United States
- Veterans Health Administration — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Abdel-Latif, Ahmed — Veterans Health Administration
- Study coordinator: Abdel-Latif, Ahmed
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.